Influence of age on long-term outcome after emergent percutaneous coronary intervention for ST-elevation myocardial

Chin Hiew1, Trent Williams, Rachael Hatton

  • 1Cardiovascular Unit, John Hunter Hospital, Newcastle, New South Wales, Australia.

Insights

Age alone does not predict adverse outcomes in elderly patients undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Instead, comorbidities and procedural factors influence outcomes, guiding future treatment strategies for this demographic.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Geriatric Cardiology

Background:

  • Percutaneous coronary intervention (PCI) is preferred over thrombolysis for ST-elevation myocardial infarction (STEMI).
  • Elderly patients with STEMI face higher in-hospital mortality.
  • Predictors of adverse outcomes and late follow-up data in elderly STEMI patients are limited.

Purpose of the Study:

  • To evaluate early and late outcomes of emergent PCI for STEMI in all patients.
  • To identify predictors of late adverse events after PCI for STEMI.
  • To determine if advanced age alone predicts adverse outcomes in STEMI patients undergoing PCI.

Main Methods:

  • Retrospective review of patients undergoing emergent PCI for STEMI.
  • Inclusion of patients who had primary PCI or rescue PCI for failed thrombolysis.
  • Data collected from December 2003 to December 2007 at a single tertiary referral center.

Main Results:

  • 269 patients underwent primary or rescue PCI for STEMI.
  • Patients aged 70 years or older had more cardiovascular risk factors and coronary artery disease.
  • Thrombolysis in Myocardial Infarction (TIMI) 3 flow predicted good outcomes; recurrent in-hospital ischemia, prior aspirin use, and discharge creatinine predicted poor outcomes. Age was not an independent predictor of adverse outcomes.

Conclusions:

  • Increased mortality in elderly STEMI patients undergoing PCI is linked to comorbidities and procedural issues, not age itself.
  • Future strategies should focus on identifying elderly STEMI patients who will benefit most from invasive procedures.
  • Optimizing STEMI management in the elderly requires a nuanced approach beyond chronological age.
Abstract

Related Concept Videos

Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...